CureVac (NASDAQ:CVAC) Reaches New 12-Month High – What’s Next?

CureVac N.V. (NASDAQ:CVAC) hit a new 52-week high on Tuesday . The company traded as high as $4.42 and last traded at $4.4050, with a volume of 128272 shares. The stock had previously closed at $4.32.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of CureVac in a research report on Tuesday, December 16th. One research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $6.83.

CureVac Price Performance

The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.69 and a current ratio of 3.70. The company has a market cap of $988.66 million, a P/E ratio of 6.12 and a beta of 1.77. The firm has a 50 day moving average price of $5.06 and a two-hundred day moving average price of $5.29.

CureVac (NASDAQ:CVAC) last issued its earnings results on Monday, November 24th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.07. CureVac had a net margin of 199.92% and a negative return on equity of 23.03%. The business had revenue of $63.53 million for the quarter, compared to analysts’ expectations of $21.40 million. On average, analysts predict that CureVac N.V. will post 0.72 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd grew its holdings in CureVac by 354.8% in the second quarter. Caitong International Asset Management Co. Ltd now owns 5,608 shares of the company’s stock worth $30,000 after purchasing an additional 4,375 shares during the period. Headlands Technologies LLC purchased a new position in CureVac in the 2nd quarter worth approximately $35,000. Integrated Wealth Concepts LLC boosted its stake in CureVac by 25.0% during the 1st quarter. Integrated Wealth Concepts LLC now owns 15,000 shares of the company’s stock valued at $42,000 after purchasing an additional 3,000 shares during the last quarter. Kathmere Capital Management LLC bought a new stake in shares of CureVac in the 2nd quarter worth $60,000. Finally, L2 Asset Management LLC bought a new stake in CureVac in the 2nd quarter worth about $70,000. 17.26% of the stock is currently owned by institutional investors.

About CureVac

CureVac N.V. is a clinical-stage biopharmaceutical company that specializes in the research, development and commercialization of messenger RNA (mRNA)-based medicines and vaccines. Leveraging its proprietary mRNA platform, the company seeks to harness the body’s natural protein production processes to address a range of diseases, with particular emphasis on prophylactic vaccines for infectious diseases as well as therapeutic candidates in oncology. CureVac’s technology is designed to deliver optimized mRNA sequences for in vivo expression, aiming to improve stability, translational efficiency and immunogenicity compared with conventional approaches.

Founded in 2000 and headquartered in Tübingen, Germany, CureVac has built a pipeline spanning early- to late-stage clinical programs.